Foldyne Research International focuses on creating and advancing precision compounds for the treatment of diseases with unmet medical needs, in various drug classes. Our innovative approach to drug development has resulted in patentable intellectual property for compounds that are ready to advance into preclinical trials. Contact us for our translational compound catalogue and pricing.
Examples of successful targeting are the inhibition of the WNT5a/ROR2 signalling pathway involved in multiple cancer types and the design of a new, picomolar inhibitor on the Maternal Leucine Zipper Kinase (MELK). MELK as a target is validated in Intrinsic Diffuse Pontine Glioma (DIPG) cell lines and xenograft mouse models, and is as well highly overexpressed in other types of cancerous brain tissue. Predominantly active during embryonic development, the target is non-toxic and the inhibitor might become a magic bullet in the treatment of DIPG. Preclinical/Phase I results indicate the possibility of a high efficacy, low-dose cure without adverse effects.